Attachment #2 Overview of Follow-up

Similar documents
Attachment #2 Overview of Follow-up

Cystectomies and bladder preservation: What you need to know

Appendix 4 Urology Care Pathways

BLADDER CANCER: PATIENT INFORMATION

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Bladder Cancer Guidelines

A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

Urologic Oncology Section

Chemotherapy Treatment Algorithms for Urology Cancer

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

THE UROLOGY GROUP

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Treatment Testicular Cancer Guidelines

Male genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital.

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

UROLOGICAL CANCER 2010 COMPARATIVE AUDIT REPORT

Glossary of Terms Primary Urethral Cancer

MEDitorial March Bladder Cancer

A patient with recurrent bladder cancer presents with the following history:

UNDERSTANDING BLADDER CANCER

BLADDER CANCER CONTENT CREATED BY. Learn more at

Upper Tract Urothelial Carcinomas (UTUCs)

Pathology Driving Decisions

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

UROLOGY CANCER 2009 COMPARATIVE AUDIT REPORT

BLADDER HEALTH. Muscle Invasive Bladder Cancer: A Patient Guide

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

Quiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Surveillance after Treatment of Malignancies. John M. Burke, M.D. March 2013

Exercise. Discharge Summary

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

Cancer Cases Treated and Results

When to Integrate Surgery for Metatstatic Urothelial Cancers

Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy?

DEPARTMENT OF ONCOLOGY ELECTIVE

3.1 Investigations for Patients Presenting with Haematuria Table 1

Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors

Neoplasms of the Prostate and Bladder

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:

Part II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Carcinoma of the Renal Pelvis and Ureter Histopathology

Laparoscopic Surgery. The Da Vinci Robot. Limits of Laparoscopy. What Robotics Offers. Robotic Urologic Surgery: A New Era in Patient Care

Highlighting Clinical Trials Muscle Invasive Bladder Cancer

Quiz. b. 4 High grade c. 9 Unknown

AUA Guidelines for Invasive Bladder Cancer: What s New?

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Haematuria Clinic. Information for patients Urology PROUD TO MAKE A DIFFERENCE SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST

Staging and Grading Last Updated Friday, 14 November 2008

Bladder Cancer Basics For the Newly Diagnosed

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends

Trimodality Therapy for Muscle Invasive Bladder Cancer

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer

Information for Patients. Bladder Cancer. English

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

Prostate Overview Quiz

6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).

Kaiser Oakland Urology

Retroperitoneal Lymph Node Dissection (RPLND) Department of Urology Information for patients

Urology An introduction to cut up DR J R GOEPEL

Testicular Cancer. Regional Follow-up Guidelines

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Urinary Bladder, Ureter, and Renal Pelvis

KIDNEY HEALTH. Kidney Masses and Localized Kidney Tumors: A Patient Guide

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

GUIDELINES ON TESTICULAR CANCER

COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Prostate Cancer Case Study 2. Medical Student Case-Based Learning

What is endometrial cancer?

Section Activity Activity Description Details Reference(s)

Muscle-invasive bladder cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

URINARY DIVERSIONS. Winter 2016 Dr P. O Malley

We are gong to focus on: Unit 9. Before we begin: Chronic Renal Failure/Uremia ESRD/Dialysis Prostate Cancer Testicular Cancer Renal Cancer

Deciding on treatment: a step on your journey.

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Doppler ultrasound of the abdomen and pelvis, and color Doppler

Procedure Specific Information Sheet Open Radical Prostatectomy

Muscle-invasive bladder cancer

Citation International journal of urology (2. Right which has been published in final f

SAMPLING OF POST NEPHRECTOMY CANCER CARE (5)

Glossary. A Abdomen an anatomical term that refers to the area between the chest and pelvis, which contains the bowels and other organs

25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES

INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER

General information about prostate cancer

2016 Oncology Institute Annual Report

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

AllinaHealthSystems 1

1. Benign Prostate Hyperplexia (BPH) 2. Prostate Cancer (PCa)

ESMO Consensus Empfehlungen 2017

RESIDENCY TRAINING PROGRAMME IN UROLOGY CERTIFICATION APPLICATION FORM PARTICIPATING INSTITUTE(S)

Radical Cystectomy A Patient s Guide

Guidelines for the Management of Bladder Cancer

Bladder Cancer Handbook

Transcription:

Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer to home or with a primary care doctor. All tests should be sent to Dr. Pierorazio by email, fax or mail. Dr. Pierorazio would like to see or speak to all patients one month following surgery to confirm recovery and wound healing. Contents Bladder cancer after radical cystectomy (Page 1) Kidney cancer after radical or partial nephrectomy (Page 2) Upper tract urothelial cancer after nephroureterectomy (Page 3) Testicular cancer after orchiectomy or RPLND (Page 4) Prostate cancer after radical prostatectomy (Page 5) BLADDER CANCER AFTER RADICAL CYSTECTOMY 3 weeks after surgery - Urinary conduit: exam by enterostomal nurse - Neobladder or Indiana Pouch -catheter removed, learn self-catheterization -if suprapublic catheter present, will be removed when comfortable with self-catheterization -referral to physical therapy (if neobladder or needed) Low-Risk Bladder Cancer: Stage 0, Tis, or 1 Time After Surgery 4 12 24 Annually CT scan Abdomen & x x Pelvis Chest -ray x x Blood Test (CBC, CMP, Folate, B12) x x High-Risk Bladder Cancer: Stage 2 or greater* Time After Surgery 4-6 12 18 24 30 Ct scan -ray Blood tests (CBC, CMP, Folate, B12) CBC: complete blood count, CMP: complete metabolic panel *This schedule may be modified on an individual basis or based on the medical oncologist s recommendations

KIDNEY CANCER AFTER PARTIAL OR RADICAL NEPHRECTOMY Risk is determined by the Stage (extent) of disease. In some circumstances, Grade (aggressiveness under the microscope) will modify risk. For example, any Grade IV tumor is high-risk. Low-Risk Kidney Cancer: Stage I (Cancer confined to the kidney, less than 7cm) Time After Surgery 1 month 4 12 2 Annually Blood and Urine Tests x CT scan (Abdomen and x Pelvis) Chest -ray x Intermediate-Risk Kidney Cancer: Stage II (Cancer confined to the kidney, greater than 7cm) Time After Surgery 1 month 4 12 2 3 Annually Blood and Urine Tests x CT scan (Abdomen and x Pelvis) Chest -ray High-Risk Kidney Cancer: Stage III or Higher (Cancer outside of the kidney), or Grade IV at any stage Time After Surgery 1 month 4 8 12 18 24 Annually Blood and Urine Tests (Until 5 ) Chest -ray (Until 5 ) (After 5 )

UPPER TRACT UROTHELIAL CANCER (CANCER OF THE RENAL PELVIS OR URETER) AFTER NEPHROURETERECTOMY or URETERECTOMY Low-Risk Urothelial Carcinoma: Non-Invasive or Low-Grade (Stage 0 or 1) Time After Surgery Year 1 Year 2-3 Year 4-5 After 5 Blood and Urine Tests At 1, 4 and 12 Annually At 4 and 12 Annually Chest -ray At 4 and 12 Annually Cystoscopy Every 4 Annually High-Risk Urothelial Carcinoma: Invasive (Stage 2 or greater) or Positive Lymph Nodes Every 1-2 Time After Surgery Year 1 Year 2-3 Year 3-5 After 5 Blood and Urine Tests At 1, 4 and 12 Annually Every 4 Annually Chest -ray Every 4 Annually Cystoscopy Every 4

TESTICULAR CANCER Active Surveillance after Orchiectomy: Stage 1(A or B) Seminoma Time after surgery Year 1 Year 2 3-5 After 5 At 3, 6 and Every 12 Every 1-2 12 Chest -ray At 6 and 12 Every 12 Every 1-2 Every year Every 1-2 Active Surveillance after Orchiectomy Stage 1(A or B) Non-seminoma germ cell (NSGCT) Time after surgery Year 1 2-3 4-5 After 5 At 3, 6 and Once per Every 1-2 12 Chest -ray At 6 and 12 (1A); Every 3 (1B) year -12 Every 1-2 Every year Every 1-2 After Primary RPLND: No active cancer If active cancer, the follow-up regimen will be determined after consideration of chemotherapy. Time after surgery 1-2 2-5 After 5 At 4, 12 and 24 Chest -ray At 4, 12 and 24 Annually -4

After Post-chemotherapy RPLND: No active cancer or Teratoma If active cancer, the follow-up regimen will be determined after consideration of chemotherapy. Time after surgery 1-2 2-5 After 5 At 3, 12 and 24 Chest -ray Annually -4 PROSTATE CANCER 1 month after surgery for post-operative appointment After Radical Prostatectomy: Low Risk (Gleason 6, PSA <10, pt2) Time after surgery Year 1 After 1 year PSA At 6 and 12 Annually After Radical Prostatectomy: Intermediate Risk (Gleason 7, PSA 10-20, pt3a) Time after surgery Year 1 Year 2-3 After 3 PSA Annually After Radical prostatectomy: High Risk (Gleason 8-10, PSA >20, pt3b, N1 or positive surgical margins) Pending the pathology results, we will consider referrals to Medical and Radiation oncology as appropriate Time after surgery Year 1-2 After 2 PSA Annually